Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics
- 6 November 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (22) , 9328-9341
Abstract
Peptide hybrids (phybrids) comprising covalently linked peptide hormones can leverage independent biological pathways for additive or synergistic metabolic benefits. PEGylation of biologics offers enhanced stability, duration, and reduced immunogenicity. These two modalities can be combined to produce long-acting therapeutics with dual pharmacology and enhanced efficacy. Compound 10 is composed of an exenatide (AC2993) analogue, AC3174, and an amylinomimetic, davalintide (AC2307), with an intervening 40 kD PEG moiety. It displayed dose-dependent and prolonged efficacy for glucose control and body weight reduction in rodents with superior in vitro and in vivo activities compared to those of a side-chain PEGylated phybrid 6. In diet-induced obese (DIO) rats, the weight-loss efficacy of 10 was similar to that of a combination of PEG-parents 3 and 4. A single dose of 10 elicited sustained body weight reduction in DIO rats for at least 21 days. Compound 10’s terminal half-life of ∼27 h should translate favorably to weekly dosing in humans.Keywords
This publication has 65 references indexed in Scilit:
- A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic propertiesBiochemical Pharmacology, 2013
- A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed miceDiabetologia, 2013
- Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and α
v
β 3 integrinProceedings of the National Academy of Sciences, 2011
- Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptideDiabetes, Obesity and Metabolism, 2011
- Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weightInternational Journal of Obesity, 2009
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in MiceDiabetes, 2009
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodentsNature Chemical Biology, 2009
- Design of a Long Acting Peptide Functioning as Both a Glucagon-like Peptide-1 Receptor Agonist and a Glucagon Receptor AntagonistJournal of Biological Chemistry, 2006
- Antibody Multispecificity Mediated by Conformational DiversityScience, 2003
- Isomeric AntibodiesScience, 2003